•
Protocol CN138012-016: A Randomized, Double Blind Comparison
of the efficacy and Safety of Aripiprazole Intramuscular
Formula, Haloperidol, or Placebo in the treatment of Acutely
Agitated Patients with a Diagnosis of Schizophrenia or Schizoaffective
Disorder.
•
Protocol 041509: A Double blind, Long Term extension trial
to asses the efficacy and Safety of qd and bid dose regimes
of up to 30 mg / day Org 5222 (Asenapine) in subjects with
Schizophrenia.
•
Protocol 041019: A 6 week, multicenter, double blind, randomized,
placebo controlled trial to asses the efficacy and Safety
of qd and bid dose regimes of up to 30 mg / day Org 5222
(Asenapine) versus placebo in subjects suffering from an
acute exacerbation of Schizophrenia.
•
PROTOCOL R076477-SCH-305: A Randomized, Double Blind Placebo
Controlled Parallel Group, Dose Response Study to Evaluate
the Efficacy and Safety of Three Fixed Doses of Extended
Release OROS (R) Paliperidone (3, 9, and 15 mg) and Olanzepine
(10mg) in the Treatment of Subjects with Schizophrenia
•
Protocol AZ 5077IL/0089 (Clears Trial) A Multicenter, open
label, flexible dose, parallel group evaluation of the cataractogenic
potential of Quetiapine fumarate (SEROQUEL TM ) and Risperidone
(RISPERDAL TM ) in the long term treatment of patients with
Schizophrenia and Schizoaffective Disorder.
